Astorg Joins Nordic Capital and Novo Holdings in Recapitalization of ERT

ERT Merges with Bioclinica to Create Global Clinical Trial Endpoint Leader

December 10, 2020

Healthcare Services

ERT has merged with Bioclinica to create a global leader in clinical trial endpoint technology, combining Bioclinica's imaging and eClinical capabilities with ERT's expertise in eCOA, cardiac safety, respiratory and wearables. The transaction was completed in 2021 with Cinven (Bioclinica's owner) becoming a significant minority shareholder in ERT alongside Nordic Capital, Astorg and Novo Holdings A/S.

Evestia Clinical Merges with Atlantic Research Group

July 15, 2025

Healthcare Services

Kester Capital-backed Evestia Clinical has merged with US-based Atlantic Research Group (ARG) to create a larger independent specialist CRO with dual headquarters in Letchworth, UK and Charlottesville, VA. The combination expands Evestia's US footprint and adds neurology and late-stage clinical trial capabilities while broadening therapeutic expertise across oncology, rare diseases, immunology and inflammation.

Astorg Acquires Normec Group from Summit Partners

June 24, 2020

Industrial Services

Astorg has signed a definitive agreement to acquire Normec Group, a Netherlands-headquartered provider of testing, inspection, certification and compliance services, from Summit Partners. The deal — agreed in partnership with Normec management — is expected to close in Q3 2020; financial terms were not disclosed and Astorg said it will support Normec's international expansion.

Macquarie Capital Invests in Earth Resources Technology (ERT)

May 21, 2024

Government & Public Sector

Macquarie Capital's Growth and Technology team has made a growth investment in Earth Resources Technology (ERT), a Laurel, Maryland–based data systems and technology company serving U.S. federal agencies. The founders will remain with the business and Macquarie will take board seats to support ERT as it expands its client base, capabilities and service offerings into adjacent markets.

Arlington Capital Partners Makes Majority Investment in Everest Clinical Research Corporation

December 7, 2020

Healthcare Services

Washington, D.C.-based private equity firm Arlington Capital Partners has made a majority investment in Toronto-headquartered Everest Clinical Research Corporation, with Everest's founding shareholders and senior management rolling equity and continuing to lead the company. Everest is a full-service contract research organization (CRO) with ~300 employees across Toronto, Little Falls (NJ) and Shanghai; Arlington will support expansion of service lines, capabilities and headcount to drive growth.

Everest Clinical Research (Arlington) Acquires August Research

November 7, 2023

Healthcare Services

Everest Clinical Research, a portfolio company of Arlington Capital Partners, has acquired European contract research organization August Research. The deal expands Everest's European footprint and clinical trial (CTS) and pharmacovigilance (PV) capabilities across 14 countries; August's founders will remain with the business. Financial terms were not disclosed.